

REMARKS

Claims 1-14 have been cancelled. Newly added Claims 15 and 16 are based on original claims 2, 4, 6, and 8 as well as the application at page 1, line 6 and line 25.

The Examiner has rejected Claim 14 under 35 USC 112, first paragraph as not enabling for treating diseases/conditions other than seizure or inflammatory pain. It is the Examiner's position that one of ordinary skill in the art cannot use the invention as disclosed for diseases/conditions other than seizure or inflammatory pain because in the examples in the application the patients that are treated have convulsions. However, those of ordinary skill in the art, there being nothing stated to the contrary, based on the disclosure in the application, would treat patients suffering from other diseases/conditions analogously to the convulsing patients in the examples. Accordingly, the amendment to the claim and the above argument render this rejection moot. Therefore, it is requested that the examiner reconsider and withdraw this rejection of the claims.

The claims have been rejected under 35 USC 102 by the Examiner as being anticipated by admitted prior art of record (page 9, lines 11-20) of the specification. This alleged prior art of record discloses the use of KCNQ2/3 for convulsion and inflammatory pain, not subject matter of the pending claims as amended. Accordingly, it is requested that this rejection of the claims be reconsidered and withdrawn.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



Bonnie L. Deppenbrock
Attorney for Applicants
Registration No. 28,209

Date: 15 January, 2004
Glaxo SmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
Telephone: (919) 483-1577
Facsimile: (919) 483-7988